Secretary of State Antony Blinken visits the Bay Area

Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Future of Pharma Insights: Q&A with Olon Group

We sat down with Andrea Conforto, VP of CDMO at Olon Biotech.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership

Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines

Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs.
Antheia’s 2023 in Review: A Year Of Transformation

Dear colleagues, friends, and supporters: As we approach 2024, we want to take a moment to look back over an absolutely astounding year of progress for our business and give thanks to the many who made it possible. Nearly a decade of hard work culminated in an industry-first achievement here at Antheia. In August, we […]
Addressing the Drug Shortage Crisis: Transforming Pharma Supply Chains

Drug shortages in the U.S. have become an urgent issue over the last few years. So much so that in 2020, the Administration issued an Executive Order for the U.S. FDA to establish an Essential Medicines List of critical drugs that are deemed medically necessary, with the ultimate goal of identifying ways to protect and […]
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines

Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains

We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Fixing essential medicine shortages: obstacles and opportunities

Global health experts and governing bodies agree that everyone has a right to access the medicines they need. The COVID-19 pandemic and resulting drug shortages have underscored the critical need to protect this right…
Transforming Medicinal Supply Chains

In the Future of Everything radio show, Stanford bioengineers Russ Altman and Christina Smolke discuss advances in synthetic biology and the rise of opioids made from yeast.